Oncogenic MET as an Effective Therapeutic Target in Non-Small Cell Lung Cancer Resistant to EGFR Inhibitors: The Rise of the Phoenix.

Cancer Discov

Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute IRCCS, and Department of Oncology, University of Torino School of Medicine, Candiolo, Torino, Italy.

Published: December 2016

AI Article Synopsis

  • Concomitant inhibition of EGFR and MET may help non-small cell lung cancer patients with specific mutations, but larger trials haven't supported this combo's effectiveness in a broader patient group.
  • A new study suggests that certain genetic factors contribute to the effectiveness of targeting both EGFR and MET.
  • It also identifies a mutation in MET that causes resistance to traditional MET inhibitors but remains susceptible to alternative MET-targeting drugs.

Article Abstract

Anecdotal reports have shown that concomitant inhibition of EGFR and MET can be clinically effective in patients with non-small cell lung cancer carrying EGFR mutations and MET amplification, but large phase III trials in genetically unselected individuals have failed to confirm the benefit of this combination therapy. A new study corroborates the evidence that lung cancer susceptibility to EGFR and MET blockade is sustained by genetically based activation of both targets and identifies a mutation in MET that confers acquired resistance to standard MET inhibitors hitting the active kinase, yet is vulnerable to other MET-directed compounds with a different binding mode. Cancer Discov; 6(12); 1306-8. ©2016 AACR.See related article by Bahcall and colleagues, p. 1334.

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-1181DOI Listing

Publication Analysis

Top Keywords

lung cancer
12
non-small cell
8
cell lung
8
egfr met
8
met
5
oncogenic met
4
met effective
4
effective therapeutic
4
therapeutic target
4
target non-small
4

Similar Publications

Objective: Pulmonary pleomorphic carcinoma is a relatively rare and aggressive subtype of non-small cell lung cancer (NSCLC), with a poor prognosis and early recurrence, and is resistant to conventional therapies. This study investigated the efficacy of immune checkpoint inhibitors (ICIs) in improving the survival outcomes of patients with pulmonary pleomorphic carcinoma with postoperative recurrence.

Methods: We conducted a retrospective analysis of 71 patients with pulmonary pleomorphic carcinoma who underwent pulmonary resection at Tokyo Medical University Hospital between 2008 and 2022.

View Article and Find Full Text PDF

Interferon-gamma (IFN-γ) is an important cytokine associated with antitumor immunity and has been implicated in the pathogenesis and progression of lung cancer. Nevertheless, no bibliometric analyses have been published in this field to date, and thus we aim to address this gap in knowledge. A search of the Web of Science (WOS) for literature related to the treatment of lung cancer with IFN-γ was conducted from 2002 to 2024.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors (ICIs) are currently the primary approach for managing NSCLC. However, numerous combination therapies are currently under investigation. Our goal is to investigate the overall efficacy and safety of ICIs and taxane-based chemotherapy.

View Article and Find Full Text PDF

Background: Spatial data are often aggregated by area to protect the confidentiality of individuals and aid the calculation of pertinent risks and rates. However, the analysis of spatially aggregated data is susceptible to the modifiable areal unit problem (MAUP), which arises when inference varies with boundary or aggregation changes. While the impact of the MAUP has been examined previously, typically these studies have focused on well-populated areas.

View Article and Find Full Text PDF

Oral Microalgae-Based Biosystem to Enhance Irreversible Electroporation Immunotherapy in Hepatocellular Carcinoma.

Adv Sci (Weinh)

January 2025

Department of Surgery, Center for Cancer Medicine, the Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.

Irreversible electroporation (IRE) is a novel local tumor ablation technique that can potentially stimulate immune responses. However, IRE alone cannot effectively activate the immune system or prevent distant metastases. Therefore, this study utilized the biocompatibility of Chlorella vulgaris (C.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!